Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript
Our actual results may differ materially from those discussed during this conference call due to the risks and uncertainties inherent in our business which include, our dependence on the successful commercialization of OFIRMEV, the potential that will require substantial additional funding in order to effectively commercialize OFIRMEV, and the risk that we may not be able to raise sufficient capital when needed or at all, the risk that delays in commercially launching OFIRMEV would enable competitors to further entrench their existing products or develop and bring new products to market before OFIRMEV, our ability to ensure an adequate and continued supply of OFIRMEV, and our ability to comply with the terms of and draw down additional amounts under a loan agreement, and the potential for an event of default under a loan agreement, the impact of healthcare reform legislation and our ability to timely complete a required post-marketing efficacy study of OFIRMEV in infants and neonates.
These and other risks are detailed in our prior press releases and periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements and we undertake no obligation to revise or update such statements. All forward looking-statements are qualified by this cautionary statement.
This caution is made under the Safe Harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. If anyone has not seen our press release issued earlier today, you can access it on our website at www.cadencepharm.com. Additionally, this conference call is being webcast through the company’s website and will be archived there for future reference. Ted?
Ted SchroederThank you, Bill. Good morning, everyone, and thank you for joining us today. I’ll start by discussing the recent FDA approval of OFIRMEV and our ongoing preparations to launch the product. Next Bill will provide an overview of our third quarter and year-to-date financial results, and then we’ll open the call to your questions.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV